Lower Mortality Seen With Hemodiafiltration for Kidney Failure
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 21, 2023 -- For patients with kidney failure, the use of high-dose hemodiafiltration results in a lower risk for death from any cause compared with high-flux hemodialysis, according to a study published online June 16 in the New England Journal of Medicine to coincide with the annual congress of the European Renal Association, held from June 15 to 18 in Milan.
Peter J. Blankestijn, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a randomized trial involving patients with kidney failure who received high-flux hemodialysis for at least three months. All the patients were deemed to be candidates for a convection volume of at least 23 L per session (as required for high-dose hemodiafiltration). The patients were randomly assigned to high-dose hemodiafiltration or continuation of conventional high-flux hemodialysis (683 and 677 patients, respectively). Patients were followed for a median of 30 months.
In the hemodiafiltration group, the mean convection volume during the trial was 25.3 L per session. The researchers found that death from any cause occurred in 17.3 and 21.9 percent of patients in the hemodiafiltration and hemodialysis groups, respectively (hazard ratio, 0.77).
"Our trial results, together with those of several other trials and large observational studies, seem to indicate that the safety of hemodiafiltration was acceptable, provided that hygienic and microbiologic rules are fully respected," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in...
Leukocyte Glucose Index, Arteriovenous Fistula Failure Linked in ESKD
MONDAY, April 22, 2024 -- For patients with end-stage kidney disease (ESKD), a high preoperative leukocyte glucose index (LGI) is associated with arteriovenous fistula (AVF)...
Risk Prediction Model Accurate for Chronic Kidney Disease
FRIDAY, April 19, 2024 -- For individuals with moderate-to-severe chronic kidney disease (CKD), a model, KDpredict, can accurately predict the risk for kidney failure and death...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.